Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

À¯¼¼Æ÷ ÀÌÁß ºÐ¼®¿¡¼­ ³ªÅ¸³­ ¼¼Æ÷ Áֱ⠵¿¾ÈÀÇ Á¾¾ç°ü·ÃÇ׿ø MAGE-3¿Í º¯ÀÌÇü p53´Ü¹éÀÇ »ó°ü¼º Relationship between Expressions of Tumor-Associated Antigen MAGE-3 and p53 Proteins during Cell Cycle by Bivariate Analysis of Flow Cytometry

´ëÇѾÏÇÐȸÁö 1999³â 31±Ç 4È£ p.784 ~ 792
¼Ò¼Ó »ó¼¼Á¤º¸
ÀåÈñ°æ/Hee Kyung Chang ±è´öÁØ/ÀÌ°­´ë/³ëȯÁß/G.Spagnoli/Deok Jun Kim/Kang Dae Lee/Hwan Jung Roh/G. Spagnoli

Abstract

¼­·Ð
Á¾¾ç ¾ïÁ¦ À¯ÀüÀÚÀÎ ¾ß»ýÇü p53À» ÀÌ¿ëÇÑ ¾ÏÀÇ À¯ÀüÀÚ Ä¡·á¿¡ ´ëÇÑ ¿¬±¸°¡ ±Ù·¡ ½ÃµµµÇ
°í ÀÖÀ¸¸ç, ÀÌ´Â ºÎºÐÀûÀ¸·Î ¾ß»ýÇü p53ÀÇ ¼¼Æ÷ÁÖ±â Á¶Àý±â´É¿¡ ±Ù°Å¸¦ µÎ°í ÀÖ´Ù. ¶ÇÇÑ
Nijmanµî¿¡ ÀÇÇÏ¸é ¸î Á¾·ùÀÇ ¾ß»ýÇü p53 ÆéŸÀ̵å´Â Á¶Á÷ÀûÇÕÇ׿ø(histocompatability
antigen; HLA) A 0201 ºÐÀÚ¿Í Ä£È­·ÂÀÌ ÀÖ°í, ÀÌ Á¶Á÷ ÀûÇÕ Ç׿ø°ú °áÇÕ¿¡ ÀÇÇØ ¼¼Æ÷µ¶¼º
T ¸²ÇÁ±¸ (cytotoxic T lymphocyte; CTL)¸¦ È°¼ºÈ­½ÃÅ°´Â °ÍÀ¸·Î º¸°íµÇ¾î ÀÖ´Ù. ÀÌ¿Í °°
ÀÌ ¼¼Æ÷µ¶¼º T ¸²ÇÁ±¸¸¦ ÀÌ¿ëÇÑ ¾ÏÀÇ ¸é¿ªÇÐÀû Ä¡·á·Î¼­ ÃÖ±Ù °¢±¤ ¹Þ°í ÀÖ´Â Á¾¾ç °ü·ÃÇ×
¿øÀÌ MAGE À¯ÀüÀÚÀÌ´Ù. MAGE À¯ÀüÀÚ´Â ¾Ç¼º Èæ»öÁ¾ ¼¼Æ÷ÁÖ¿¡¼­ À¯·¡ÇÑ °ÍÀ¸·Î¼­, °íȯ
°ú ŹÝÀ» Á¦¿ÜÇÑ Á¤»óÁ¶Á÷À̳ª ¾ç¼º Á¾¾ç¿¡¼­´Â ¹ßÇöµÇÁö ¾Ê´Â ¹Ý¸é ¾Ç¼º Á¾¾ç¿¡¼­ ¹ßÇöµÇ
´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. MAGE À¯ÀüÀÚ »ê¹°À» ¹ßÇöÇÏ´Â Á¾¾ç¼¼Æ÷´Â CTL¿¡ ÀÇÇØ ÀνĵǴÂ
µ¥, ¿©±â¿¡´Â Á¦1±Þ Á¶Á÷ÀûÇÕ Ç׿ø°úÀÇ °áÇÕÀ» ÇÊ¿ä·Î ÇѴ٠ƯÈ÷ Çѱ¹Àο¡¼­ ÈçÈ÷ Ç¥ÇöµÇ´Â
HLA-A2 ¶Ç´Â HLA-B44 µîÀº 12Á¾ ÀÌ»óÀÇ MAGE À¯ÀüÀÚ Áß MAGE-3 À¯ÀüÀÚÀÇ ¹ßÇö¿¡
°ü°èÇÏ°í(5,6), µÎ°æºÎÀÇ ÆíÆò»óÇǾϿ¡¼­ MAGE-3 À¯ÀüÀÚÀÇ ¹ßÇöÀÌ º¸°íµÇ¾ú´Ù. ±×·¯³ª
MAGE-3 À¯ÀüÀÚÀÇ ´Ü¹éÀÌ ¾Ç¼º ¼¼Æ÷¿¡¼­¸¸ ¹ßÇöµÇ¾î Á¾¾ç °ü·Ã Ç׿øÀ̶ó°í ¾Ë·ÁÁ® ÀÖÀ¸³ª,
¾Ç¼º Á¾¾ç ¹ß»ý¿¡ °ü¿©ÇÏ´Â ±âÀüÀ» ºñ·ÔÇÏ¿© ÀÌ¿¡ ´ëÇÑ »ý¹°ÇÐÀûÀÎ ±â´É, ƯÈ÷ ¼¼Æ÷ÁÖ±â¿Í
°ü·ÃµÈ ¿¬±¸´Â Àü¹«ÇÑ ½ÇÁ¤ÀÌ´Ù.
¾Ç¼º Á¾¾çÀÇ ¹ß»ý ±âÀüÀº Á¶ÀýµÇÁö ¾Ê´Â ¼¼Æ÷ºÐ¿­·Î ¼³¸íÇÒ ¼ö ÀÖ´Ù. Áï, ¼¼Æ÷ÁÖ±â¿Í °ü·Ã
µÈ °¢Á¾ À¯ÀüÀÚÀÇ DNAº¹Á¦ ÀÌ»óÀº ¼¼Æ÷³» ½ÅÈ£ Àü´Þ °æ·ÎÀÇ ÀÌ»ó°ú ÇÔ²² Á¾¾ç À¯ÀüÀÚÀÇ
È°¼ºÈ­³ª Á¾¾ç ¾ïÁ¦ À¯ÀüÀÚÀÇ º¯À̸¦ À¯¹ßÇÏ¿© ±Ã±ØÀûÀ¸·Î Á¤»ó¼¼Æ÷ÀÇ ¾Ç¼º º¯È¯À» ÃÊ·¡ÇÑ
´Ù. ¼¼Æ÷ ÁÖ±â Áß¿¡¼­ ¹ß¾Ï °úÁ¤¿¡¼­ °¡Àå ¹®Á¦°¡ µÇ°í ÀÖ´Â ½Ã±â´Â Á¤»óÀûÀ¸·Î ¿ÜºÎ ½ÅÈ£
¿¡ ¹ÝÀÀÇÏ¿© ¼¼Æ÷ºÐ¿­·Î µé¾î°¥ ¼öµµ ÀÖ°í ÇÑÆíÀ¸·Î´Â G0 ±â·Î ÈÄÅðÇϸ鼭
¼¼Æ÷Áֱ⿡¼­ ¹þ¾î³¯ ¼öµµ ÀÖ´Â G1 ±â¶ó°í ¾Ë·ÁÁ® ÀÖ´Ù. ÀÌ·¯ÇÑ
G1 ±â Á¶Àý ÀÎÀÚ Áß ¾ß»ýÇü P53Àº DNA°¡ ¼Õ»óµÈ ¼¼Æ÷¸¦ G1
±â¿¡ ¸ØÃß°Ô Çؼ­ ¼Õ»óµÈ DNA¸¦ º¹±¸ÇÒ ½Ã°£À» ÁÖ´Â G checkpoint Á¶ÀýÀÚ
±â´ÉÀ» º¸ÀδÙ. Á¤»ó ¼¼Æ÷ÀÇ DNA°¡ ¼Õ»óÀ» ¹ÞÀ¸¸é ¾ß»ýÇü p53Àº p21
(WAF1/CIP1)ÀÇ »ý¼ºÀ» À¯µµ¶ó¸ç, ÀÌ·¸°Ô »ý¼ºµÈ p21Àº cyclin,
cyclin dependent kinases (CDKs), PCNA (proliferating cell nuclear antigen) º¹ÇÕü¿Í °á
ÇÕÇÔÀ¸·Î½á ¼¼Æ÷ ÁÖ±â ÁøÇà¿¡ Áß¿äÇÑ ±â´ÉÀ» ´ã´çÇÏ´Â CDKsÀÇ È°¼ºÀ» ¾ïÁ¦ÇÏ¿© ¼¼Æ÷ÁÖ±â
¸¦ G1 ±â¸¦ Á¤Áö½ÃÅ°°Ô ÇÑ´Ù´Â °ÍÀÌ´Ù. ±×·¯³ª ¾Ç¼º Á¾¾ç¿¡¼­¿Í °°ÀÌ ¾ß»ýÇü
p53 À¯ÀüÀÚ¿¡ º¯ÀÌ°¡ ÀϾ °æ¿ì¿¡´Â ¾î¶² ƯÁ¤ÇÑ ¼¼Æ÷Áֱ⿡ º¯ÀÌÇü p53 (ÀÌÇÏ Mtp53)
¹ßÇöÀÌ ÁýÁߵǴÂÁö¿¡ ´ëÇؼ­´Â Àß ¾Ë·ÁÁ® ÀÖÁö ¾ÊÀ» »Ó´õ·¯ À¯¼¼Æ÷ ºÐ¼®ÀÇ µ¿ÀÏÇÑ ¹æ¹ýÀ¸·Î
Á¶»çÇÑ ¼Ò¼öÀÇ ±âÁ¸ ¿¬±¸¿¡¼­Á¶Â÷ »ó¹ÝµÈ °á°úµéÀÌ º¸°íµÇ¾î ÀÖ´Ù. Áï, MorkveµîÀº ±â°üÁö
¾Ï¿¡¼­ º¯ÀÌÇü p53Àº ¾ß»ýÇü p53°ú´Â ´Þ¸® °¢ ¼¼Æ÷ Áֱ⿡¼­ ´Ù¾çÇÑ ¹ßÇöÀ» º¸¿´´Ù°í ÇÏ¿´
À¸³ª KuroseµîÀº ÀÎü ÆíÆò»óÇÇ¾Ï A43l ¼¼Æ÷ÁÖ¿¡¼­´Â ¸ðµç Áֱ⿡ °ÉÃÄ º¯ÀÌÇü p53ÀÌ ºñ½Á
ÇÑ ³ôÀº ¹ßÇöÀ» º¸°íÇÏ¿´´Ù. ƯÈ÷ ¼¼Æ÷ Áֱ⿡ µû¶ó º¯ÀÌÇü p53ÀÇ ¹ßÇöÀÌ Ç×»ó¼ºÀ» º¸ÀÌ´Â
°æ¿ì´Â ±×·¸Áö ¾ÊÀº °æ¿ìº¸´Ù Á¾¾çÀÇ ¾Ç¼ºµµ°¡ ³ô´Ù°í º¸°íÇÏ¿´´Ù. ÀÌ¿¡ ÀúÀÚ´Â ÇÏÀεΠÆí
Æò¼¼Æ÷¾ÏÁ¾ ¼¼Æ÷ÁÖ PNUH-12¸¦ ´ë»óÀ¸·Î MAGE-3¿Í Mtp53 ´Ü¹éÀÇ ¹ßÇöÀ» Á¶»çÇÏ°í, ¼¼Æ÷
ÁÖ±â¿ÍÀÇ °ü·Ã¼º¿¡ ÁÖ¸ñÇÏ¿© ÀÌ ´Ü¹éµéÀÇ ¹ßÇöÀÇ »ó°ü¼ºÀ» ¾Ë¾Æº¸°íÀÚ À¯¼¼Æ÷ ´Üµ¶ ¹× ÀÌÁß
ºÐ¼®À» ÀÌÇàÇÏ¿´´Ù. ¾Æ¿ï·¯ ¸é¿ªÁ¶Á÷È­ÇÐÀû ¿°»öÀ¸·Î Á¾¾ç¼¼Æ÷ ³»¿¡¼­ÀÇ ÀÌµé ´Ü¹éÀÇ ¹ßÇö
À§Ä¡¸¦ È®ÀÎÇÏ°íÀÚ ÇÏ¿´´Ù.

Purpose : MAGE (melanoma antigen gene) is a tumor associated antigen, presented
by HLA class I molecules, which is recognized by cytotoxic T 1ymphocytes. The
expression of MAGE proteins are confined to malignant tumor tissues, except for the
normal testis and placental tissues. Therefore, MAGE may be a potential target for
immunotherapy of malignant tumors. However, biological aspects associated with the cell
cycle are not yet described.
Materials and Methods : The material used for this study was a novel human
squamous cell carcinoma cell line (PNUH-12) from the hypopharynx, which had one
point mutation of 78th base, C to G, in exon 7 of p53 gene. To understand the role of
MAGE in relation to cell cycle and its relationship with p53 as the G1 checkpoint
regulator, the expressions of MAGE-3 protein and mutant p53 (Mtp53) were accessed
by flow cytometry and immunohistochemistry. Double stains for MAGE-3/Mtp53 was
analyzed with bivariate flow cytometry, DNA histograms using MAGE-3/PI (DNA) and
Mtp53/PI (DNA) were also analyzed.
Results : The expression rate of MAGE-3 and Mtp53 were 83% and 85%,
respectively. MAGE-3 was expressed in cytoplasm, while Mtp53 were expressed in the
nuclei of the tumor cells on the immunohistochemical sections. With bivariate analyses,
coexpression rate of MAGE-3/Mtp53 was 0.96, and MAGE-3 and Mtp53 constantly
showed high levels throughout the cell cycle except G0.
Conclusions : These results mean that (1) MAGE-3 might have yet unknown
relationship with mutant p53, (2) expressions of MAGE-3 and Mtp53 are not dependent
on the cell cycle in PNUH-12 hypopharyngeal squamous carcinoma cell line, and
suggest that MAGE-3 might have a role as important as p53 during the development of
malignant tumors.

Å°¿öµå

PNUH-12 cell line; Bivariate flow cytometry; MAGE-3 protein; Mutant p53; Cell cycle;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS